Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures
OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.
Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development
Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.
Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.